Pulse Biosciences (NASDAQ:PLSE) Trading Up 7.6% – Still a Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares traded up 7.6% during trading on Friday . The company traded as high as $20.89 and last traded at $21.15. 90,376 shares changed hands during trading, a decline of 26% from the average session volume of 121,426 shares. The stock had previously closed at $19.66.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Thursday, January 2nd.

Pulse Biosciences Trading Up 6.9 %

The stock has a fifty day moving average of $18.57 and a 200-day moving average of $17.76.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter in the prior year, the business earned ($0.19) earnings per share.

Insider Activity

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert W. Duggan purchased 55,256 shares of the company’s stock in a transaction on Friday, December 13th. The shares were purchased at an average price of $17.18 per share, with a total value of $949,298.08. Following the completion of the purchase, the director now directly owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 71.50% of the company’s stock.

Institutional Trading of Pulse Biosciences

A number of institutional investors have recently modified their holdings of PLSE. SG Americas Securities LLC purchased a new position in Pulse Biosciences in the fourth quarter valued at approximately $193,000. Franklin Resources Inc. acquired a new stake in shares of Pulse Biosciences in the third quarter worth $378,000. Creative Planning raised its stake in shares of Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares during the period. Barclays PLC lifted its holdings in shares of Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after acquiring an additional 23,738 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Pulse Biosciences during the 3rd quarter worth $588,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.